Skip to main content
Erschienen in: Journal of Community Health 1/2019

21.08.2018 | Original Paper

Successful Implementation of a Shared Medical Appointment Model for Hepatitis C Treatment at a Community Health Center

verfasst von: Jacqueline Hodges, Jessica Reyes, Joyce Campbell, Wesley Klein, Alysse Wurcel

Erschienen in: Journal of Community Health | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Highly efficacious direct acting antiviral (DAA) therapy for treatment of Hepatitis C Virus (HCV) infection is largely inaccessible to communities facing a shortage of available specialist providers. Though less demanding than previous interferon regimens, DAA therapy requires patients to adhere to 8–12 weeks of daily treatment, which can be challenging for some patient populations. Duffy Health Center, located on Cape Cod, Massachusetts, provides integrated medical, mental health and case management services to people who are homeless or at risk for homelessness. The goal of this manuscript is to evaluate the outcomes of treatment of HCV infection with a shared medical appointment (SMA) model. The primary outcome was sustained virologic response (SVR-12), or HCV RNA ≤ 15 IU/mL at 12 weeks post-treatment. There were 102 patients recruited, with a total of 104 treatments administered. Over three-fourths of patients who attended one SMA visit (78 of 102) continued in SMA for the duration of treatment. Of these patients opting for SMA, 99% (77 of 78) completed the full treatment course, and 91% (71 of 78) of SMA patients achieved SVR-12. DAA therapy provided by non-specialist providers using the SMA model yielded comparable response rates to those achieved by specialist providers, and has the potential to substantially increase access to HCV treatment for patient populations within high-risk communities.
Literatur
1.
Zurück zum Zitat Edlin, B. R., Eckhardt, B. J., Shu, M. A., Holmberg, S. D., & Swan, T. (2015). Toward a more accurate estimate of the prevalence of hepatitis C in the United States. Hepatology, 62(5), 1353–1363.CrossRefPubMedPubMedCentral Edlin, B. R., Eckhardt, B. J., Shu, M. A., Holmberg, S. D., & Swan, T. (2015). Toward a more accurate estimate of the prevalence of hepatitis C in the United States. Hepatology, 62(5), 1353–1363.CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Barocas, J. A., Beiser, M., Leon, C., Gaeta, J. M., O’Connell, J. J., & Linas, B. P. (2017). Experience and outcomes of hepatitis C treatment in a cohort of homeless and marginally housed adults. JAMA Internal Medicine, 177(6), 880–882.CrossRefPubMedPubMedCentral Barocas, J. A., Beiser, M., Leon, C., Gaeta, J. M., O’Connell, J. J., & Linas, B. P. (2017). Experience and outcomes of hepatitis C treatment in a cohort of homeless and marginally housed adults. JAMA Internal Medicine, 177(6), 880–882.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Kattakuzhy, S., Gross, C., Emmanuel, B., Teferi, G., Jenkins, V., Silk, R., et al. (2017). Expansion of treatment for hepatitis C virus infection by task shifting to community-based nonspecialist providers: A nonrandomized clinical trial. Annals of Internal Medicine, 167(5), 311–318.CrossRefPubMedPubMedCentral Kattakuzhy, S., Gross, C., Emmanuel, B., Teferi, G., Jenkins, V., Silk, R., et al. (2017). Expansion of treatment for hepatitis C virus infection by task shifting to community-based nonspecialist providers: A nonrandomized clinical trial. Annals of Internal Medicine, 167(5), 311–318.CrossRefPubMedPubMedCentral
4.
6.
Zurück zum Zitat Yoo, E. R., Perumpail, R. B., Cholankeril, G., Jayasekera, C. R., & Ahmed, A. (2017). Expanding Treatment access for chronic hepatitis C with task-shifting in the era of direct-acting antivirals. Journal of Clinical and Translational Hepatology, 5(2), 130–133.PubMedPubMedCentral Yoo, E. R., Perumpail, R. B., Cholankeril, G., Jayasekera, C. R., & Ahmed, A. (2017). Expanding Treatment access for chronic hepatitis C with task-shifting in the era of direct-acting antivirals. Journal of Clinical and Translational Hepatology, 5(2), 130–133.PubMedPubMedCentral
8.
Zurück zum Zitat Grebely, J., Dalgard, O., Conway, B., Cunningham, E. B., Bruggmann, P., Hajarizadeh, B., et al. (2018). Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): An open-label, single-arm, phase 4, multicentre trial. The Lancet Gastroenterology & Hepatology, 3(3), 153–161.CrossRef Grebely, J., Dalgard, O., Conway, B., Cunningham, E. B., Bruggmann, P., Hajarizadeh, B., et al. (2018). Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): An open-label, single-arm, phase 4, multicentre trial. The Lancet Gastroenterology & Hepatology, 3(3), 153–161.CrossRef
9.
Zurück zum Zitat Liao, J. M., & Fischer, M. A. (2017). Restrictions of hepatitis C treatment for substance-using medicaid patients: Cost versus ethics. American Journal of Public Health, 107(6), 893–899.CrossRefPubMedPubMedCentral Liao, J. M., & Fischer, M. A. (2017). Restrictions of hepatitis C treatment for substance-using medicaid patients: Cost versus ethics. American Journal of Public Health, 107(6), 893–899.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Do, A., Mittal, Y., Liapakis, A., Cohen, E., Chau, H., Bertuccio, C., et al. (2015). Drug authorization for sofosbuvir/ledipasvir (Harvoni) for chronic HCV infection in a real-world cohort: A new barrier in the HCV care cascade. PLoS ONE, 10(8), e0135645.CrossRefPubMedPubMedCentral Do, A., Mittal, Y., Liapakis, A., Cohen, E., Chau, H., Bertuccio, C., et al. (2015). Drug authorization for sofosbuvir/ledipasvir (Harvoni) for chronic HCV infection in a real-world cohort: A new barrier in the HCV care cascade. PLoS ONE, 10(8), e0135645.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Martin, M. T., Telebak, E., Taylor, P. A., & Volozhina, O. (2016). Development of a specialty medication prior-authorization service at an urban academic medical center. American Journal of Health-System Pharmacy, 73(15), 1174–1179.CrossRefPubMed Martin, M. T., Telebak, E., Taylor, P. A., & Volozhina, O. (2016). Development of a specialty medication prior-authorization service at an urban academic medical center. American Journal of Health-System Pharmacy, 73(15), 1174–1179.CrossRefPubMed
12.
Zurück zum Zitat Akiyama, M. J., Agyemang, L., Arnsten, J. H., Heo, M., Norton, B. L., Schackman, B. R., et al. (2018). Rationale, design, and methodology of a trial evaluating three models of care for HCV treatment among injection drug users on opioid agonist therapy. BMC Infectious Diseases, 18(1), 74.CrossRefPubMedPubMedCentral Akiyama, M. J., Agyemang, L., Arnsten, J. H., Heo, M., Norton, B. L., Schackman, B. R., et al. (2018). Rationale, design, and methodology of a trial evaluating three models of care for HCV treatment among injection drug users on opioid agonist therapy. BMC Infectious Diseases, 18(1), 74.CrossRefPubMedPubMedCentral
Metadaten
Titel
Successful Implementation of a Shared Medical Appointment Model for Hepatitis C Treatment at a Community Health Center
verfasst von
Jacqueline Hodges
Jessica Reyes
Joyce Campbell
Wesley Klein
Alysse Wurcel
Publikationsdatum
21.08.2018
Verlag
Springer US
Erschienen in
Journal of Community Health / Ausgabe 1/2019
Print ISSN: 0094-5145
Elektronische ISSN: 1573-3610
DOI
https://doi.org/10.1007/s10900-018-0568-z

Weitere Artikel der Ausgabe 1/2019

Journal of Community Health 1/2019 Zur Ausgabe